AbbVie Says Acute Myeloid Leukemia Trial Meets Endpoints
March 23 2020 - 9:28AM
Dow Jones News
By Michael Dabaie
AbbVie Inc. said its trial of venclexta in combination with
azacitidine versus azacitidine in combination with placebo met its
dual primary endpoints.
The trial met the endpoints of statistically significant
improvement of overall survival and composite complete remission
rate for patients with previously-untreated acute myeloid leukemia
who are ineligible for intensive chemotherapy.
At the recommendation of an independent data monitoring
committee due to positive efficacy results at the first interim
analysis for overall survival, the trial results will be reported
early and the data from the trial will be submitted to the U.S. FDA
and global health authorities.
Results will be presented at a future medical meeting or
published in a peer-reviewed journal, the company said.
Venclexta is being developed by AbbVie and Roche. It is jointly
commercialized by AbbVie and Genentech, a member of the Roche
Group, in the U.S. and by AbbVie outside of the U.S.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
March 23, 2020 09:13 ET (13:13 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Aug 2024 to Sep 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Sep 2023 to Sep 2024
